High-efficiency, patented platelet therapy protocol specifically validated for both dogs and cats. Achieve 5× concentration at 80% lower cost per procedure.
PlatGen is a science-based project emerging from the Universidade de Trás-os-Montes e Alto Douro (UTAD). We are bridging the gap in veterinary regenerative medicine by providing a patented, validated protocol for high-concentration platelet therapy.
Our solution eliminates the need for expensive proprietary kits, allowing clinics to deliver superior care for both dogs and cats at a fraction of the traditional cost, backed by dual patent protection in the EU and USA.
As a future university spinoff, we combine academic rigour with a clear market focus, addressing the most underserved segments in animal health with proven, published data.
Built on peer-reviewed research and validated haematological data published by UTAD veterinary researchers.
The only protocol designed, validated and patented specifically for dogs and cats — the most underserved species in veterinary regenerative medicine.
Standard laboratory consumables only. No proprietary kits, no locked supply chains, no recurring license fees.
EU patent valid in 38 states. US patent pending. The two largest veterinary markets in the world, covered.
Our proprietary technology delivers unmatched platelet recovery, specifically validated for both canine and feline haematology, addressing a critical gap in the regenerative market.
Our double-spin centrifugation protocol is protected by granted European and pending US patents, ensuring market exclusivity.
The only therapy specifically validated for both canine and feline haematology, addressing the fastest-growing market segments.
Delivers 5× platelet concentration from minimal blood volume, outperforming standard commercial systems.
No proprietary kit dependency. Uses standard lab consumables, reducing procedure costs by up to 80%.
"For the first time, a protocol achieves ~5× platelet concentration specifically validated in both dogs and cats — outperforming all commercial systems described in veterinary literature, from only 4.5 mL of blood."
Addressing the multi-billion dollar veterinary regenerative market with a focused strategy on the most underserved and fastest-growing segments.
Current Market Leader (FDA-reviewed):
PlatGen:
Future Spin-off of the Universidade de Trás-os-Montes e Alto Douro
Vila Real · Portugal
Whether you are a veterinary clinic, an investor, or an industry partner — we want to hear from you.
Implement the PlatGen protocol for dogs and cats in your practice. Early adopter access available in EU and US.
Request Protocol InfoSeed round open · €750K · Dual-market IP. University spin-off. Peer-reviewed science for canines and felines.
Request Investor DeckOEM licensing, research partnerships, and clinical validation collaborations with leading industry players.
Explore Partnerships